Advances in Precision Medicine Oncology
Arnouk, Hilal
Advances in Precision Medicine Oncology - IntechOpen 2021 - 1 electronic resource (260 p.)
Open Access
Recent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin's drug resistance and critical side effects.
Creative Commons
English
intechopen.91507 9781839688683 9781839688676 9781839688690
10.5772/intechopen.91507 doi
Oncology
Advances in Precision Medicine Oncology - IntechOpen 2021 - 1 electronic resource (260 p.)
Open Access
Recent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin's drug resistance and critical side effects.
Creative Commons
English
intechopen.91507 9781839688683 9781839688676 9781839688690
10.5772/intechopen.91507 doi
Oncology